EGFR and lung carcinoma: Emerging evidence support the idea that 1,25-dihydroxyvitamin D3 (1,25(OH)2D3, 1,25D, calcitriol) inhibits lung cancer cell proliferation [14, 15] and opposes erlotinib or osimertinib resistance in preclinical models or in EGFR-mutant LUAD patients [16, 17].